ArticleThe AAPS journal2025
A Novel Oral Disintegrating Tablet Containing Aprepitant Nanocrystal Developed by Freeze-Drying Technology: An Effective Strategy to Enhance Aprepitant Bioavailability.
Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study developed a novel aprepitant (APT) nanocrystal-containing oral disintegrating tablet (ODT) to enhance the oral bioavailability of APT through "rapid disintegration". APT nanocrystal suspension (APT-NS) was prepared via miniaturized media milling, with a particle size of 199.25 ± 12.88 nm, a polydispersity index (PDI) of 0.148 ± 0.026 and zeta potential of -24.82 ± 1.28 mV. The APT-NS was spray-dried into dry powders (APT-NCS) and further processed into ODTs via freeze-drying. Through central composite design-response surface methodology (CCD-RSM) optimization, the final APT-ODT formulation demonstrated rapid disintegration (< 5 s) and excellent dissolution (> 95% within 2 min). Results of X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FTIR) confirmed the absence of crystalline transformation or chemical degradation during processing. Pharmacokinetic results demonstrated that both APT-NS and APT-ODTs exhibited approximately twofold higher AUC
Indexed as
Identifiers
41372558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.